Widening the BRCAness therapeutic window for its synthetic lethality effects with PARP inhibitors.

PARP inhibitors are linked to replication-associated DNA damage that broadens the BRCAness phenotype beyond BRCA-dependent synthetic lethality, widening their therapeutic window.

• Why it matters: The field needs mechanisms and biomarkers that explain PARP inhibitor cytotoxicity beyond single-strand break repair, to expand who may benefit.
• What they did: The review integrates mechanistic evidence on replication-linked lesions, including Okazaki fragment maturation defects and replication gap accumulation, with CRISPR-based screen findings.
• The result: Disruptions in DNA replication and repair pathways are associated with a broader BRCAness phenotype, supporting new combination strategies to extend PARP inhibitor applicability beyond current regimens.

AI summary of the abstract · may contain errors · not medical advice · read the paper.